Yes. DUPIXENT treatment decreased FeNO (up to 35% reduction from baseline by Week 2a) and circulating concentrations of eotaxin-3, total IgE (up to 83% reduction from baseline at Week 96b), allergen-specific IgE, TARC, and periostin in asthma subjects relative to placebo. DUPIXENT decreased these markers of type 2 inflammation and sustained the effects throughout treatment. In addition, there was an impact on eosinophil activation and trafficking (up to 35% median reduction from baseline at Week 96b). The mechanism of dupilumab action has not been definitively established.1,6-12



Explore the role these biomarkers have in the pathogenesis of asthma